XML 71 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments - Narrative (Details)
 3 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
interest_rate_swap
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
interest_rate_swap
Dec. 31, 2018
USD ($)
Mar. 31, 2019
USD ($)
Derivative [Line Items]          
Number of interest rate swaps held | interest_rate_swap 19   19    
Notional amount of derivative $ 30,666,000,000 $ 29,742,000,000 $ 30,666,000,000 $ 29,742,000,000  
Face amount of debt         $ 5,000,000,000.0
Pre tax net unrealized gain (loss) on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales     31,000,000    
Equity investments without readily determinable fair values 420,000,000 568,000,000 420,000,000 568,000,000  
Unrealized gains based on favorable observable price changes     20,000,000 167,000,000  
Unrealized loss related to unfavorable observable price changes     13,000,000 26,000,000  
Upward price adjustment 109,000,000   109,000,000    
Downward price adjustment 21,000,000   21,000,000    
Available-for-sale debt securities included in Short-term investments 749,000,000   749,000,000    
Available-for-sale debt securities maturing within five years 933,000,000   933,000,000    
Cash and cash equivalents 9,676,000,000 7,965,000,000 9,676,000,000 7,965,000,000  
Payments of contingent consideration     85,000,000 244,000,000  
Fair value of loans payable and long-term debt, including current portion 28,800,000,000 25,600,000,000 28,800,000,000 25,600,000,000  
Long term and short term debt 26,300,000,000 25,100,000,000 26,300,000,000 25,100,000,000  
Accounts receivable factored 2,700,000,000 1,100,000,000      
Funds collected from factoring of receivable, held in restricted cash 256,000,000   256,000,000    
Cash collateral received from counterparties 34,000,000 107,000,000 34,000,000 107,000,000  
Right to reclaim cash 0 0 $ 0 0  
Customer Concentration Risk | Accounts Receivable | McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc.          
Derivative [Line Items]          
Percentage of accounts receivable represented by customers with largest balances (as percent)     35.00%    
Afferent Pharmaceuticals          
Derivative [Line Items]          
Payments of contingent consideration       175,000,000  
Level 2          
Derivative [Line Items]          
Cash and cash equivalents 9,700,000,000   $ 9,700,000,000    
Cash equivalents 8,900,000,000   8,900,000,000    
Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Notional amount of derivative 14,728,000,000 14,390,000,000 14,728,000,000 14,390,000,000  
Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Notional amount of derivative $ 15,938,000,000 $ 15,352,000,000 $ 15,938,000,000 $ 15,352,000,000  
Maximum | Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum planning cycle of hedges (no more than)     2 years    
Maximum | Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum planning cycle of hedges (no more than)     1 year